AAA617: clinical trials recruiting now

Phase breakdown

Conditions being studied

Recruiting trials involving AAA617

• A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
  NCT07226986 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 22 locations
• A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
  NCT06531499 · Phase: Phase 1 · Ages: 18 Years to 100 Years · Sex: Male · 21 locations
• An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
  NCT05939414 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: Male · 144 locations
• Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
  NCT05803941 · Phase: Phase 4 · Ages: 18 Years to 100 Years · Sex: Male · 54 locations

Common questions

How many recruiting trials involve AAA617?

4 recruiting trials across 4 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.